FDA accepts Unicycive's Oxylanthanum Carbonate NDA resubmission, sets PDUFA date of March 25, 2027

Unicycive Therapeutics announced the FDA accepted its resubmission of the New Drug Application for Oxylanthanum Carbonate, with a PDUFA date of March 25, 2027. Shares rose 6.8% in premarket trading.

Detected & updated continuously · Source: Nebula